Vaishali Sanchorawala, MD Hear my name
Professor
Boston University Chobanian & Avedisian School of Medicine
Medicine
Hematology & Medical Oncology

MBBS, Seth G.S. Medical College

Pronouns: she/her/hers



72 East Concord Street, K-503, Boston, MA 02118
820 Harrison Avenue, Boston, MA 02118 (clinic address)

Expertise includes: AL amyloidosis - clinical trials, treatment; Amyloidosis; Stem cell transplantation; Myeloma.

Dr Vaishali Sanchorawala is the Director of Stem Cell Transplantation program at Boston Medical Center; Director of Amyloidosis Center at Chobanian and Avedisian School of Medicine; Skinner Professor of Amyloidosis Research in the Department of Medicine; Associate Editor of Amyloid: The Journal of Protein Folding Disorders and Secretary of the International Society of Amyloidosis for the term 2020-2022.

Her research has led and defined the field in AL amyloidosis. She is recognized as one of the leading international experts and a key opinion leader in amyloidosis. With numerous publications and meeting presentations, she is one of the pioneers in the field of clinical research in AL amyloidosis. Her work in the treatment of AL amyloidosis has resulted in the evolution of the standard of care for these patients. I am currently heading several clinical trials in the treatment of AL amyloidosis, two of which were conducted nationally through the Southwest Oncology Group (SWOG0115 and SWOG1702), completed accrual in a timely fashion and led to publications in a peer-reviewed journals.

Dr Sanchorawala is part of the faculty at major international conferences in amyloidosis and has given many invited talks at national and international meetings. She is active in various non-profit organizations, regulatory authorities, and funding bodies as an expert on amyloidosis. She is at present a member of the Executive Steering Committee of Amyloidosis Research Consortium which is developing pathways to education, patient voice, development of treatment and access to novel therapies. She has participated in meetings with the FDA for enhancing the amyloidosis drug development pathway, guidance for more efficient and successful programs. She serves on the advisory board of number of leading pharmaceutical partners for drugs in AL amyloidosis.

She has helped to create and cultivate the next generation of physician-scientists in the area of clinical research in amyloidosis. She regularly attends a number of patient information seminars and support group meetings in the US. She also created the first “live tweet event” for patients and care givers to ask questions via social media.

Outside of roles of direct research and clinical care, she has an interest inworking in charity organizations. She helps cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteers regularly at “Cradles to Crayons” charity, non-profit organization.

Diversity, Equity, Inclusion and Accessibility

I stand firmly committed to diversity, equity, inclusion, and justice as a core value of my professional and personal life. I have a strong commitment to making a difference to people from underprivileged and marginalized communities. I strive to bridge access to the most cutting-edge diagnostic modalities and treatments for members of all underrepresented groups—e.g., ethnic, racial, religious, and sexual minorities, among others.

I also support diversity and equity through my research efforts, by studying racial and ethnic inequalities that are pervasive within the field of medicine. In particular, I am struck by the low representation of minorities in clinical trials, despite having a disproportionately higher risk of certain diseases. I mentored a fellow to conduct a study investigating racial and ethnic disparities in a rare plasma cell disorder called AL amyloidosis, and found that differences in health outcomes among minorities were largely explained by lower educational level and later recognition of disease, rather than race and ethnicity itself. We concluded that, in order to mitigate disparities in this rare disease, earlier disease detection and concerted efforts to reduce economic and/or language barriers are key.

My influence extends beyond the groundbreaking and paradigm-shifting work in the field of amyloidosis. In addition to my scientific achievements, I have an interest in working in charity organizations. I help cook meals for ~300 underserved individuals at a meal center in Massachusetts (1-2 times a month) and volunteer regularly at “Cradles to Crayons” charity, non-profit organization. I consistently seek opportunities to understand, respect and serve communities in need.

Associate Director
Boston University Chobanian & Avedisian School of Medicine
Amyloidosis Center


Member
Boston University
BU-BMC Cancer Center


Director
Boston Medical Center
Stem Cell Transplantation Program
Hematology & Medical Oncology

Secretary
International Society of Amyloidosis


Executive committee
Amyloidosis Research Consortium


Associate Editor
Amyloid: The Journal of Protein Folding disorders




SPORE in Multiple Myeloma
06/01/2021 - 05/31/2023 (Key Person / Mentor)
Dana-Farber Cancer Institute NIH NCI
5P50CA100707-19

Evaluating Plasma Neurofilament Light Chain as an Early Biomarker for Polyneuropathy in V122I Hereditary Transthyretin Amyloidosis
01/01/2022 - 12/31/2022 (Key Person / Mentor)
PI: K. H. Vincent Lau, MD
Amyloidosis Foundation


A phase 3 randomized, controlled, open-label, multicenter, safety and efficacy study of dexamethasone plus MLN9708 or physician's choice of treatment administered to patients with relapsed or refracto
09/28/2012 - 09/27/2022 (PI)
Millennium Pharmaceuticals, Inc.


Defining a molecular signature of cardiac tissue dysfunction in systemic immunoglobulin light-chain amyloidosis
07/01/2020 - 06/30/2022 (Key Person / Mentor)
PI: Camille Edwards, MD
American Society of Hematology


A Phase I/II Trial of Pomalidomide and Dexamethasone for the treatment of patients with AL Amyloidosis
03/01/2012 - 02/28/2021 (PI)
Celgene Corporation


Molecular Imaging of Primary Amyloid Cardiomyopathy
04/01/2017 - 03/31/2020 (Co-Investigator)
The Brigham and Women's Hospital, Inc. NIH NHLBI
5R01HL130563-04

A Phase I Dose-Escalation Study of Carflizomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
12/12/2013 - 12/12/2019 (PI)
Academic Myeloma Consortium


Phase II study of the combination Bendamustine and Dexamethasone in patients with relapsed AL amyloidosis
09/04/2012 - 09/09/2019 (Subcontract PI)
Trustees Of Columbia University In The City Of New York Cephalon, Inc


A phase 1, open label, dose escalation study of intravenous administration of single agent NEOD001 in subjects with light chain (AL) amyloidosis
05/08/2013 - 05/07/2019 (PI)
Onclave Therapeutics Limited, d/b/a Prothena Therapeutics Limited


An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients with Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further
04/01/2011 - 03/03/2019 (PI)
Millennium Pharmaceuticals, Inc.


Showing 10 of 17 results. Show All Results

M24-209: An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of ABBV-383 in AL Amyloidosis
07/16/2024 - 07/15/2027 (PI)
AbbVie Inc.

54767414AMY3001
11/17/2017 - 11/17/2026 (PI)
Janssen Research and Development, LLC

CAEL-101 301: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta
09/23/2020 - 09/22/2026 (PI)
Caelum Biosciences, Inc.

CAEL-101 302: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Sta
09/23/2020 - 09/22/2026 (PI)
Caelum Biosciences, Inc.

NEOD001-301: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
06/23/2021 - 06/22/2025 (PI)
Prothena Biosciences Limited

A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
05/19/2022 - 05/18/2025 (PI)
Janssen Research and Development, LLC

DARATUMUMAB, POMALIDOMIDE AND DEXAMETHASONE (DPd) IN RELAPSED/ REFRACTORY LIGHT CHAIN AMYLOIDOSIS PATIENTS PREVIOUSLY EXPOSED TO DARATUMUMAB
07/23/2020 - 01/22/2025 (Subcontract PI)
PI: Vaishali Sanchorawala, MD
Weill Cornell Medical College Janssen Scientific

DFCI 19-291: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone…
12/23/2019 - 12/22/2024 (Subcontract PI)
PI: Vaishali Sanchorawala, MD
Dana Farber Cancer Institute Millennium Pharm

STI-6129-001: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
12/01/2020 - 11/30/2023 (PI)
Sorrento Therapeutics, Inc.

A Phase II randomized single-blind study to evaluate the activity and safety of low dose oral…
04/23/2020 - 04/22/2023 (PI)
Karyopharm Therapeutics Inc.

Showing 10 of 17 results. Show All Results

Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Abdallah M, Arters F, Patel J, Edwards C, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand K, Szalat R. Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis. Blood Adv. 2024 Dec 10; 8(23):5935-5938.View Related Profiles. PMID: 39348709
     
  2. Dodge MC, Prokaeva T, Mendelson L, Joshi T, Sanchorawala V, Kataria Y. High-Sensitivity and Conventional Cardiac Troponin-I Assays in AL Amyloidosis. J Appl Lab Med. 2024 Nov 04.View Related Profiles. PMID: 39495058
     
  3. Anand S, O'Neill-Dee M, Sanchorawala V, Verma A. Light Chain (AL) Amyloidosis for Nephrologists - Treatment Standard. Nephrol Dial Transplant. 2024 Oct 07.View Related Profiles. PMID: 39375844; DOI: 10.1093/ndt/gfae224;
     
  4. Muchtar E, Wisniowski B, Geyer S, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Leung N, Dispenzieri A, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Ulloa P, Sanchorawala V, Szalat R, Dooley K, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Gillmore J, Lachmann H, Wechalekar A, Gertz MA. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis. JAMA Oncol. 2024 Oct 01; 10(10):1362-1369.View Related Profiles. PMID: 39088206; PMCID: PMC11295065; DOI: 10.1001/jamaoncol.2024.2629;
     
  5. Sanchorawala V. Systemic Light Chain Amyloidosis. Reply. N Engl J Med. 2024 Sep 26; 391(12):1165-1166. PMID: 39321377
     
  6. Sanchorawala V, Barroso B, Shelton AC, Goetz E, Mendelson L, Joshi T, Burke NJ, Sloan JM, Staron A. Defying the Odds: 30 Years in AL Amyloidosis Research, Recent Barriers to Clinical Trial Enrollment. Blood Adv. 2024 Sep 18.View Related Profiles. PMID: 39293090
     
  7. Staron A, Mendelson LM, Joshi T, Burke N, Sanchorawala V. Factors impeding organ recovery despite a deep haematological response in patients with systemic AL amyloidosis. Br J Haematol. 2024 Sep 14.View Related Profiles. PMID: 39275899
     
  8. Anand SK, Staron A, Mendelson LM, Joshi T, Burke N, Sanchorawala V, Verma A. Machine-learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease. Am J Hematol. 2024 Sep 11.View Related Profiles. PMID: 39257247; DOI: 10.1002/ajh.27472;
     
  9. Muchtar E, Gertz MA, Mwangi R, Hassan H, Dispenzieri A, Leung N, Buadi FK, Dingli D, Staron A, Sanchorawala V. Long-term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system. Am J Hematol. 2024 Nov; 99(11):2118-2126.View Related Profiles. PMID: 39207186
     
  10. Chakraborty R, Zanwar S, Hegenbart U, Bhutani D, Gertz MA, Dispenzieri A, Kumar SK, D'Souza A, Patwari A, Cowan AJ, Chen G, Milani P, Palladini G, Sanchorawala V, Bodanapu G, Schönland S, Lentzsch S, Muchtar E. Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy. Blood. 2024 Aug 28.View Related Profiles. PMID: 39197073
     
Showing 10 of 254 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 254 publications over 27 distinct years, with a maximum of 19 publications in 2020 and 2022

YearPublications
19941
19982
19991
20014
20021
20035
20046
20055
200611
20076
20082
20097
201012
201112
201210
20135
201410
201510
201611
201715
201817
201916
202019
202115
202219
202315
202417

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.

Recent (within 3 months)

New study underway in Boston for people with advanced stage of AL amyloidosis

The Boston Globe 10/13/2024

Older

: Early diagnosis key in combating the deadly effects of AL amyloidosis

MSN 6/27/2024

Early diagnosis key in combating the deadly effects of AL amyloidosis

News Medical 6/27/2024

Review of pathogenesis, research and treatment of amyloidosis published in New England Journal of Medicine

Scienmag 6/26/2024

Review highlights advances and future needs in AL amyloidosis treatmenthttps://medicalxpress.com/news/2024-06-highlights-advances-future-al-amyloidosis.html

Medical Xpress 6/26/2024

There’s New Proof Crispr Can Edit Genes Inside Human Bodies

WIRED 9/22/2022

Young Black Patients With AML Face Significantly Worse Outcomes

Oncology Times 8/5/2022

Stem Cell Transplantation Shows Promise in AL Amyloidosis

Global Genes 7/20/2022

Stem cell transplantation produces prolonged survival with improved safety in patients with AL amyloidosis

News Medical 7/14/2022

Stem cell transplantation for AL amyloidosis leads to long-term survival and possible cure in selected patients

Medical Xpress 7/14/2022

Dr. Sanchorawala on the Impact of Depth of Renal and Cardiac Response on Survival in AL Amyloidosis

Onc Live 9/10/2021

Honoring 20 Outstanding Women, Woman of the Year 2021 and Lifetime Achievement Award Video Released

India New England News 3/25/2021

Vaishali Sanchorawala: Her Pioneering Research Into the Rare Disease Amyloidosis Defines the Field

India New England 2/24/2021

18th Annual Woman of the Year Awards Gala Postponed Until Next Spring: April 30

INDIA New England News 9/3/2020

Daratumumab Safe And Effective Option For Treating Light Chain (AL) Amyloidosis

Medical Dialogues 2/4/2020

2015 Research mentor award
2015 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2011 Research Mentoring Award nomination
2011 Schwartz Center for Compassionate Healthcare: Compassionate Caregiver Award
2007-2009 Robert Dawson Evans Clinician Award
2000 IBMTR/ABMTR: Mortimer M. Bortin Award for best abstract
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Amyloidosis [C18.452.845.500]
Stem cell transplantation
Clinical research
QoL

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Education Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:
  • Email (see 'Contact Info')

72 East Concord Street, K-503
Boston MA 02118
Google Map


Sanchorawala's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department